Clinical Trial Update: CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial update evaluating CIMAvax-EGF vaccine in combination with nivolumab and pembrolizumab for advanced or metastatic non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CIMAvax-EGF vaccine (EGF vaccine)
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING